Contact
searchSearch
HMP Global
Login

NANETS

News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology
Video Thumbnail
Videos
Emerging Data on Alpha-Emitter Therapies
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving roles of alpha and beta emitters, novel isotopes in development, and the balance between efficacy and toxicity that will define next-generation radioligand therapy.
Experts reflect on evolving...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Mechanism of Action: Beta vs Alpha Emitters
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and long-term data from ALPHAMEDIX-02 and other alpha-emitter trials, including efficacy, toxicity patterns, and key differences between actinium- and lead-based compounds.
Experts analyze early and...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Practical Application and Patient Selection for PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor receptor expression, use of molecular imaging, and ongoing studies exploring alpha-emitting radioligand therapies and sequencing strategies in advanced NETs.
The panel examines tumor...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
Examining the Evidence for Lutetium-Based PRRT
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from pivotal trials that evaluated progression-free survival outcomes, treatment sequencing, and considerations for first-line PRRT use.
Experts discuss data from...
11/18/2025
Radiopharmaceutical Education Institute
Video Thumbnail
Videos
The Current NET Treatment Landscape and Unmet Needs
11/18/2025
Thomas Hope, MD; Amir Iravani, MD, FRACP; Daneng Li, MD; Jonathan Strosberg, MD
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving treatment landscape for neuroendocrine tumors (NETs), highlighting approved systemic and liver-directed therapies and ongoing challenges in treatment sequencing.
Experts review the evolving...
11/18/2025
Radiopharmaceutical Education Institute
News
Obrixtamig Demonstrates Promising Efficacy in DLL3-High Extrapulmonary Neuroendocrine Carcinoma
10/28/2025
Janelle Bradley
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3 bispecific T-cell engager, demonstrated a 40% objective response rate and durable, manageable activity in patients with DLL3-high extrapulmonary neuroendocrine carcinoma, according to a phase 1 trial.
Obrixtamig, a DLL3/CD3...
10/28/2025
Oncology
News
TAE and cTACE Show Comparable Efficacy for Liver-Dominant Neuroendocrine Tumor Metastases
10/28/2025
Janelle Bradley
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international...
10/28/2025
Oncology
News
212Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute

Recent News

News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology
News
TAE and cTACE Show Comparable Efficacy for Liver-Dominant Neuroendocrine Tumor Metastases
10/28/2025
Janelle Bradley
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international randomized trial show transarterial embolization (TAE) and conventional chemoembolization (cTACE) demonstrated comparable efficacy for liver-dominant neuroendocrine tumor metastases, though TAE was associated...
Findings from an international...
10/28/2025
Oncology
News
212Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use